MicroPort Scientific Corporation has announced the publication of results from the TARGET-FIRST clinical trial in the New England Journal of Medicine. The study focused on the Firehawk® Drug Eluting Stent System, independently developed by the company. The results, which were also presented at the European Society of Cardiology Congress 2025 in Spain, indicate that for patients suffering from low-risk acute myocardial infarction who undergo complete revascularization with Firehawk® Stents, the duration of dual antiplatelet therapy can be reduced from 12 months to one month. This reduction does not increase ischaemic risks and significantly lowers bleeding complications. Firehawk® Stents have been introduced in 67 countries across Asia, Europe, the Americas, Africa, and Oceania, and the company aims to focus on commercialization and promotion in North America.